Form 4: Akari Therapeutics Director Raymond Prudo-Chlebosz Granted 10 Million Stock Options

Raymond Prudo-Chlebosz, a director at Akari Therapeutics Plc, was granted 10,000,000 stock options under the company's 2023 Equity Incentive Plan.

Summary

• Raymond Prudo-Chlebosz, a director of Akari Therapeutics Plc, received 10,000,000 non-qualified stock options on June 28, 2024.
• The options have an exercise price of $0.001395 per ordinary share.
• The options were granted under the Issuer's 2023 Equity Incentive Plan.
• The options vest and become exercisable on the date of the Issuer's 2025 Annual General Meeting of Shareholders, contingent upon continued service with the Issuer.
• The reporting documents include a Power of Attorney, granting Rachelle Jacques and Wendy F. DiCicco the authority to act on behalf of Raymond Prudo-Chlebosz in matters related to securities filings.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The granting of stock options is a standard practice and indicates confidence in the director's continued service and the company's future prospects.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders, incentivizing performance and company growth.

Future Outlook

The stock options vest upon continued service and the 2025 Annual General Meeting of Shareholders, suggesting an expectation of continued involvement and contribution from the director.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize executives and align their interests with those of shareholders. This grant is part of Akari Therapeutics' broader equity incentive plan.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• Companies like Amgen, Biogen, and Gilead Sciences also utilize stock options to incentivize their directors and officers.
• The vesting schedule and exercise price are typical for such grants, aligning with industry norms for incentivizing long-term performance.

Stakeholder Impact

• Shareholders may view the stock option grant positively, as it aligns the director's interests with the company's long-term success.
• Employees may see this as a sign of stability and commitment from the company's leadership.

Next Steps

• The director must continue to provide service to the company for the options to vest.
• The company will hold its 2025 Annual General Meeting of Shareholders, which will trigger the vesting of the options if the service requirement is met.

Key Dates